ArticleActa Cardiologica Sinica2024
Empagliflozin Ameliorates Atrial and Ventricular Remodeling and Arrhythmogenesis in an Overweight Rabbit Model.
Article in Acta Cardiologica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overweight is associated with dysrhythmia and sudden cardiac death, while sodium glucose co-transporter-2 inhibitors (SGLT2-is) have been shown to possess cardioprotective effects in patients with hyperglycemia. Objectives: The aim of this study was to investigate the impact of overweight on cardiac remodeling and the potential effect of SGLT2-is. Methods: Twenty-four rabbits were randomized into 4 groups: controls (Group 1), high-fat diet (HFD) (Group 2), controls treated with empagliflozin (Group 3), and HFD treated with empagliflozin (Group 4). All rabbits underwent electrophysiologic studies and ventricular tachycardia/ventricular fibrillation (VF) inducibility tests (maximal output with shortest 1:1 cycle length pacing). Atrial and ventricular myocardium were harvested for Western blot and Trichrome staining. Results: Among all groups, Group 2 had the longest atrial effective refractory periods (ERPs) in both left and right atria, as well as the longest ventricular ERPs in both left and right ventricles. VF inducibility was highest in Group 2. The degree of fibrosis in both atria and ventricles was most severe in Group 2 and similar to that in Group 4. Enhanced calcium handling protein (CaV 1.2) expressions were noted in Group 2 compared to those in Group 1 and Group 3, respectively, and returned to baseline in Group 4. Conclusions: Overweight causes atrial and ventricular remodeling with prolongation of effective refractoriness, increased vulnerability to VF induction, upregulation of calcium handling proteins, and advanced fibrosis. Empagliflozin attenuates these remodeling effects, leading to decreased cardiac arrhythmogenicity and a reduced risk of sudden cardiac death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.